{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:35:17Z","timestamp":1793230517326,"version":"4.5.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["U01CA243075"],"award-info":[{"award-number":["U01CA243075"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Bladder cancer is an increasingly prevalent global disease that continues to cause morbidity and mortality despite recent advances in treatment. Immune checkpoint inhibitors (ICI) and fibroblast growth factor receptor (FGFR)-targeted therapeutics have had modest success in bladder cancer when used as monotherapy. Emerging data suggests that the combination of these two therapies could lead to improved clinical outcomes, but the optimal strategy for combining these agents remains uncertain. Mathematical models, specifically agent-based models (ABMs), have shown recent successes in uncovering the multiscale dynamics that shape the trajectory of cancer. They have enabled the optimization of treatment methods and the identification of novel therapeutic strategies. To assess the combined effects of anti-PD-1 and anti-FGFR3 small molecule inhibitors (SMI) on tumor growth and the immune response, we built an ABM that captures key facets of tumor heterogeneity and CD8<jats:sup>+<\/jats:sup> T cell phenotypes, their spatial interactions, and their response to therapeutic pressures. Our model quantifies how tumor antigenicity and FGFR3 activating mutations impact disease trajectory and response to anti-PD-1 antibodies and anti-FGFR3 SMI. We find that even a small population of weakly antigenic tumor cells bearing an FGFR3 mutation can render the tumor resistant to combination therapy. However, highly antigenic tumors can overcome therapeutic resistance mediated by FGFR3 mutation. The optimal therapy depends on the strength of the FGFR3 signaling pathway. Under certain conditions, ICI alone is optimal; in others, ICI followed by anti-FGFR3 therapy is best. These results indicate the need to quantify FGFR3 signaling and the fitness advantage conferred on bladder cancer cells harboring this mutation. This ABM approach may enable rationally designed treatment plans to improve clinical outcomes.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1358019","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T04:52:18Z","timestamp":1709787138000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model"],"prefix":"10.3389","volume":"15","author":[{"given":"Daniel R.","family":"Bergman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Trujillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony A.","family":"Fernald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander T.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy F.","family":"Sweis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trachette L.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.27330","article-title":"A review of the etiology and epidemiology of bladder cancer: All you need to know","volume":"14","author":"Halaseh","year":"2022","journal-title":"Cureus"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.672262","article-title":"Treating bladder cancer: engineering of current and next generation antibody-, fusion protein-, mrna-, cell-and viral-based therapeutics","volume":"11","author":"Bogen","year":"2021","journal-title":"Front Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.3390\/jpm12101745","article-title":"Advanced bladder cancer: Changing the treatment landscape","volume":"12","author":"Bilim","year":"2022","journal-title":"J Personalized Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161284","article-title":"A multimodal imaging approach for longitudinal evaluation of bladder tumor development in an orthotopic murine model","volume":"11","author":"Scheepbouwer","year":"2016","journal-title":"PloS One"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1758835919890285","DOI":"10.1177\/1758835919890285","article-title":"Targeted therapies for advanced bladder cancer: new strategies with fgfr inhibitors","volume":"11","author":"Casadei","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"102530","DOI":"10.1016\/j.ctrv.2023.102530","article-title":"Role of fgfr3 in bladder cancer: Treatment landscape and future challenges","volume":"115","author":"Ascione","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0274","article-title":"Molecular drivers of the non\u2013t-cell-inflamed tumor microenvironment in urothelial bladder cancer","volume":"4","author":"Sweis","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6940546","article-title":"A comprehensive review of us fda-approved immune checkpoint inhibitors in urothelial carcinoma","volume":"2017","author":"Hsu","year":"2017","journal-title":"J Immunol Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.575258","article-title":"Fgfr3 alterations in the era of immunotherapy for urothelial bladder cancer","volume":"11","author":"Kacew","year":"2020","journal-title":"Front Immunol"},{"key":"B10","author":"Rosenberg","year":"2021"},{"key":"B11","volume-title":"Erdafitinib (erda) vs erda plus cetrelimab (erda+ cet) for patients (pts) with metastatic urothelial carcinoma (muc) and fibroblast growth factor receptor alterations (fgfra): Final results from the phase 2 norse study","author":"Siefker-Radtke","year":"2023"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1038\/s41467-020-15424-4","article-title":"Prostatespecific antigen dynamics predict individual responses to intermittent androgen deprivation","volume":"11","author":"Brady-Nicholls","year":"2020","journal-title":"Nat Commun"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2021.06.013","article-title":"Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics","volume":"23","author":"Brady-Nicholls","year":"2021","journal-title":"Neoplasia"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1101\/2023.03.22.533721","article-title":"Adaptive therapy for ovarian cancer: An integrated approach to parp inhibitor scheduling","author":"Strobl","year":"2023","journal-title":"bioRxiv"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s11538-008-9344-z","article-title":"Mathematical model of pulsed immunotherapy for superficial bladder cancer","volume":"70","author":"Bunimovich-Mendrazitsky","year":"2008","journal-title":"Bull Math Biol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4161\/onci.1.1.17884","article-title":"Mathematical model of tumor immunotherapy for bladder carcinoma identifies the limitations of the innate immune response","volume":"1","author":"Breban","year":"2012","journal-title":"OncoImmunology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"18754","DOI":"10.1038\/s41598-023-45581-7","article-title":"Mathematical modeling of bcg-based bladder cancer treatment using socio-demographics","volume":"13","author":"Savchenko","year":"2023","journal-title":"Sci Rep"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e1019","DOI":"10.1002\/cso2.1019","article-title":"A validated mathematical model of fgfr3-mediated tumor growth reveals pathways to harness the benefits of combination targeted therapy and immunotherapy in bladder cancer","volume":"1","author":"Okuneye","year":"2021","journal-title":"Comput Syst Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178479","article-title":"Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: A mathematical model","volume":"12","author":"Lai","year":"2017","journal-title":"PloS One"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1005991","article-title":"Physicell: An open source physics-based cell simulator for 3-d multicellular systems","volume":"14","author":"Ghaffarizadeh","year":"2018","journal-title":"PloS Comput Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1007635","article-title":"Hybrid automata library: A flexible platform for hybrid modeling with real-time visualization","volume":"16","author":"Bravo","year":"2020","journal-title":"PloS Comput Biol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1101\/2022.11.13.516335","article-title":"The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous proteasome inhibitor resistant disease","author":"Miller","year":"2022","journal-title":"bioRxiv"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1101\/2022.09.12.507681","article-title":"Physipkpd: A pharmacokinetics and pharmacodynamics module for physicell","volume":"2022","author":"Bergman","year":"2022","journal-title":"Gigabyte"},{"key":"B24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41540-023-00314-4","article-title":"Physiboss 2.0: a sustainable integration of stochastic boolean and agent-based modelling frameworks","volume":"9","author":"Ponce-de Leon","year":"2023","journal-title":"NPJ Syst Biol Appl"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-2006","article-title":"In silico modeling of immunotherapy and stroma-targeting therapies in human colorectal cancer","volume":"77","author":"Kather","year":"2017","journal-title":"Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"giaa075","DOI":"10.1093\/gigascience\/giaa075","article-title":"A generalizable data-driven multicellular model of pancreatic ductal adenocarcinoma","volume":"9","author":"Aguilar","year":"2020","journal-title":"Gigascience"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1038\/s41467-021-22123-1","article-title":"Normal tissue architecture determines the evolutionary course of cancer","volume":"12","author":"West","year":"2021","journal-title":"Nat Commun"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.3390\/cells12232688","article-title":"Dynamics of fibril collagen remodeling by tumor cells: A model of tumor-associated collagen signatures","volume":"12","author":"Poonja","year":"2023","journal-title":"Cells"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.1056461","article-title":"Smore pars: A novel methodology for bridging modeling modalities and experimental data applied to 3d vascular tumor growth","volume":"9","author":"Jain","year":"2022","journal-title":"Front Mol Biosci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1011070","article-title":"Calibrating agent-based models to tumor images using representation learning","volume":"19","author":"Cess","year":"2023","journal-title":"PloS Comput Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.46471\/gigabyte.77","article-title":"Physicool: A generalized framework for model calibration and optimization of modeling projects","volume":"2023","author":"Gon\u00e7alves","year":"2023","journal-title":"GigaByte"},{"key":"B32","article-title":"Digitize your biology! modeling multicellular systems through interpretable cell behavior","author":"Johnson","year":"2023","journal-title":"bioRxiv"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/imm.2011.133.issue-2","article-title":"Cytotoxic t lymphocyte perforin and fas ligand working in concert even when fas ligand lytic action is still not detectable","volume":"133","author":"Hassin","year":"2011","journal-title":"Immunology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-0515","article-title":"Reversing t-cell exhaustion in cancer: lessons learned from pd-1\/pd-l1 immune checkpoint blockade","volume":"10","author":"Budimir","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1034\/j.1600-065X.2003.00051.x","article-title":"Activation-induced cell death in t cells","volume":"193","author":"Green","year":"2003","journal-title":"Immunol Rev"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nri2115","article-title":"Life and death in peripheral t cells","volume":"7","author":"Krammer","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.104387","article-title":"A global method for fast simulations of molecular dynamics in multiscale agent-based models of biological tissues","volume":"25","author":"Bergman","year":"2022","journal-title":"Iscience"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/eva.12994","article-title":"Cancer therapy: Attempt cure or manage drug resistance","volume":"13","author":"Hansen","year":"2020","journal-title":"Evol Appl"},{"key":"B39","doi-asserted-by":"publisher","first-page":"S1340","DOI":"10.1016\/j.annonc.2023.10.106","article-title":"Lba6 ev-302\/keynote-a39: Open-label, randomized phase iii study of enfortumab vedotin in combination with pembrolizumab (ev+ p) vs chemotherapy (chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la\/muc)","volume":"34","author":"Powles","year":"2023","journal-title":"Ann Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-023-01761-7","article-title":"Unleashing the potential of combining fgfr inhibitor and immune checkpoint blockade for fgf\/fgfr signaling in tumor microenvironment","volume":"22","author":"Ruan","year":"2023","journal-title":"Mol Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11538-023-01232-6","article-title":"Information-theoretic analysis of a model of car-4-1bb-mediated nf\u03bab activation","volume":"86","author":"Tserunyan","year":"2024","journal-title":"Bull Math Biol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1358019\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T04:52:23Z","timestamp":1709787143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1358019\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2024.1358019"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1358019","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,7]]},"article-number":"1358019"}}